Qizhen Shi
@qizhenshi.bsky.social
Professor, Medical College of Wisconsin; Senior Investigator, Versiti BRI | Gene therapy, Hemophilia, FVIII/VWF, platelets
Excited to share our new paper in Blood Advances! We show that antiplatelet drugs impair platelet gene therapy in hemophilia A, but platelet-derived FVIII still outperforms plasma FVIII under inhibition. Great work by Hongyin Yu and our VBRI team.
🔗 doi.org/10.1182/bloo...
#Hemophilia #GeneTherapy
🔗 doi.org/10.1182/bloo...
#Hemophilia #GeneTherapy
Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice
Key Points. Platelet aggregation is essential for the efficacy of platelet-FVIII gene therapy and is affected by antiplatelet agents.Platelet-FVIII retains
doi.org
January 23, 2026 at 4:32 PM
Excited to share our new paper in Blood Advances! We show that antiplatelet drugs impair platelet gene therapy in hemophilia A, but platelet-derived FVIII still outperforms plasma FVIII under inhibition. Great work by Hongyin Yu and our VBRI team.
🔗 doi.org/10.1182/bloo...
#Hemophilia #GeneTherapy
🔗 doi.org/10.1182/bloo...
#Hemophilia #GeneTherapy